Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.
MULTIFOLLICULAR OVARIES: CLINICAL AND ENDOCRINE FEATURES AND RESPONSE TO PULSATILE GONADOTROPIN RELEASING HORMONE
Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.
It is shown that polycystic ovaries, as defined by pelvic ultrasound, are very common in anovulatory women and are not necessarily associated with hirsutism or a raised serum luteinising hormone concentration.
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.
Variation in the A2 allele of the CYP17 gene is a significant factor modifying the expression of PCO/MPB in families where it has been demonstrated to segregate as a single gene disorder, but it is excluded as the primary genetic defect.
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome†‡
The international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences, and emphasizes evidence based medical therapy and cheaper and safer fertility management.
POLYCYSTIC OVARY SYNDROME: A CHANGING PERSPECTIVE
- S. Franks
- MedicineClinical Endocrinology
- 1 July 1989
The article reports clinical and endocrine features in 300 women with PCOS, and discuses its etiology and the mechanism of anovulation.
POLYCYSTIC OVARIES—A COMMON FINDING IN NORMAL WOMEN
Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.
Moderate weight loss during long-term calorie restriction is associated with a marked clinical improvement which reflects the reduction in insulin concentrations and reciprocal changes in SHBG, and may be consequent upon an increase in insulin sensitivity which, directly or indirectly, affects ovarian function.
Modern use of clomiphene citrate in induction of ovulation.
It is recommended that anovulatory women responsive to clomiphene citrate should be treated for at least 6 cycles before considering more complex or invasive methods of ovulation induction, and that treatment should probably be limited to a maximum of 12 cycles.